IL

ILJIN Life Science

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Description

ILJIN Life Science Co.

Investor Profile

ILJIN Life Science has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity rounds (top funding stages).
  • Majority of deals are located in Canada.
  • Strong thematic focus on Biopharma, Biotechnology, Health Care.

Stage Focus

  • Post Ipo Equity (100%)

Country Focus

  • Canada (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does ILJIN Life Science frequently co-invest with?

venBio Partners
North America, California, United States, San Francisco
Co-Investments: 1
Difference Capital
North America, Ontario, Canada, Toronto
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 1
Great Point Partners
North America, Connecticut, United States, Greenwich
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 1
Apple Tree Partners
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by ILJIN Life Science?

Aurinia Pharmaceuticals

Victoria, British Columbia, Canada

Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.

BiopharmaBiotechnologyHealth CareMedicalTherapeutics
Post Ipo EquityFeb 14, 2014
Amount Raised: $52,000,000